An automated gene-editing platform for breast cancer

​

Cancer is a very complicated disease but with genomic advances, the research community is able to find what genes are turned on and what genes are turned off in order to understand how cancer behaves. Current automation technology that can answer these questions at a high-throughput pace is expensive and not always available for every laboratory. Thus, by using digital microfluidics, we are developing a platform that allows us to deliver gene disruption mechanisms onto target cancer cell lines and do analysis to infer their phenotypes. We hope one day that our technology can be used for clinical diagnosis and personalized medicine to treat patients.